More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Related News Articles

Chairperson's File
Public
There is a saying that is very timely for our field: A smooth sea never made a skilled sailor. As we head into the final months of 2025, hospitals and health…
Headline
The Senate returned to Capitol Hill today and is scheduled to hold its eighth vote on the House-passed continuing resolution, but is expected to fall short of…
Headline
The AHA Sept. 29 asked the Trump administration to provide exemptions for health care personnel from the proclamation issued Sept. 19 announcing changes to the…
Headline
The Office of Science and Technology Policy issued a request for information Sept. 26 seeking feedback on federal regulations that hinder AI development,…
Headline
The House Appropriations Committee today released bill text for a continuing resolution to fund the government through Nov. 21. The bill also extends key…
Headline
Newsweek’s Access Health newsletter today features a conversation with AHA Chair Tina Freese Decker, president and CEO of Corewell Health in Michigan, where…